PHILADELPHIA, Dec. 6, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that Anthony Bonelli, President and Chief Operating Officer of Hemispherx, will be presenting at the New York Society of Securities Analysts 11th Annual Biotech/Specialty Pharma Conference located at 1177 Avenue of the Americas in New York City scheduled for December 11 - 12, 2007. Mr. Bonelli's presentation is scheduled to begin at 11:30 a.m. Eastern Standard Time on Wednesday, December 12, 2007.
Updates will be provided on FDA NDA filing initiatives with Ampligen(r), an experimental CFS (Chronic Fatigue Syndrome) therapeutic and TLR3 ligand, as well as ongoing global collaborations in vaccine enhancement, including influenza and HIV/AIDS.
To access the live audio webcast for this conference, please log on to Hemispherx's website at http://www.hemispherx.net approximately 15 minutes prior to the presentation in order to register and download any necessary software. A replay of the audio presentation will be available following the event.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(r) and the experimental therapeutics Ampligen(r), Alferon LDO and Oragens(r). Alferon N Injection(r) is approved for a category of STD infection, and Ampligen(r) and Oragens(r) represent a large portfolio of experimental RNA nucleic acids being developed for globally important viral diseases, severely debilitating disorders and biodefense applications. Hemispherx's platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has in excess of 90 issued patents comprising its core intellectual property estate, a fully commercialized product (Alferon N Injection(r)) and a GMP certified manufacturing facility for its novel pharma products. The Company is actively engaged in further expansion of its intellectual property on a world wide basis to reflect the global distribution of the various disorders which its platform technology addresses. For more information please visit www.hemispherx.net.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(r), Alferon LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon N Injection(r) do not imply that the product will ever be specifically approved commercially for these other treatment indications.